Vincere Biosciences
Company with mission to develop drugs to halt the progression of Parkinson's disease
Vincere develops small molecule therapeutics to improve mitochondrial quality. Natural mechanisms of mitochondrial quality control decline with age, leading to the neurodegeneration seen in Parkinson's disease which affects 10 million patients worldwide. Biology is complex with a rapidly growing body of knowledge. Proprietary simulation and AI from NeuroInitiative enables the Vinere team to move faster and synthesize new discoveries into efficient therapeutic programs.
Visit website: https://vincerebio.com/
Details last updated 02-Apr-2022
People at Vincere Biosciences
Vincere Biosciences News
Hanall Biopharma and Daewoong Pharmaceutical join forces with Vincere Biosciences in fight against Parkinson's
Longevity Technology - 12-Jun-2023
Strategic investment aimed at harnessing the power of collaborative innovation and AI in the pursuit of groundbreaking therapeutics
Read more...Lifespan.io summarises the proceedings of the Buck Institute's Longevity Summit
Lifespan.io (LEAF) - 20-Jan-2023
Another reminder of the amount of research, with multiple approaches, about to go into clinical trials
Read more...